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The enhancement of immune effector-
cell activity is an appealing strategy for 
the treatment of various cancers. The 
development of clinically applicable ther-
apies, however, requires preclinical assays 
that allow for the study of immunological 
interactions as well as novel agents that 
exert immunomodulatory effects. To 
date, the evaluation of chemical libraries 
of small molecules affecting antitumor 
immunity has been hampered by the lack 
of robust, sensitive and high-throughput 
scalable assays. The development of high-
throughput screening strategies is needed 
for the analysis of tumors, stromal 
cells, anticancer compounds, immune 
effector-cell subsets and their mutual 
relationship. Expanding on our previ-
ous publication,1 we adapted our high-
throughput approach to discover novel 
antitumor immunomodulatory mecha-
nisms (Fig. 1).2 We showed that phar-
macological agents (i.e., lenalidomide, 
pomalidomide, bortezomib and dexa-
methasone) as well as autologous bone 
marrow stromal cells can alter antitumor 
immunity.2 In addition, such a high-
throughput screening approach allowed 
us to identify agents that enhance or 
inhibit innate antitumor cytotoxicity by 
indirect mechanisms. Interestingly, we 
discovered that a given compound can 
display different activity profiles depend-
ing on the tumor target, for instance, 
suppressing immunity against one tumor 
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target but enhancing it against others. 
The immunomodulatory properties of a 
specific drug depend on a series of fac-
tors, including the interplay between the 
cancer cells, the immune effector cells, 
tumor microenvironment and the drug 
itself.2 Our approach allows for the analy-
sis of multiple tumor targets, compounds 
and microenvironmental conditions, to 
fully evaluate the immunomodulatory 
properties of drugs.
Conventional cytotoxic agents may 
exert part of their antitumor effects by 
activating the immune system against 
cancer cells.3–5 There has been an increas-
ing interest in the discovery of novel 
immunomodulatory agents, and these 
compounds have become key thera-
peutics for the management of multiple 
myeloma (MM).6–8 Our findings can 
have major implications for the develop-
ment of therapeutics targeting many neo-
plasms. Indeed, we demonstrated that 
our high-throughput scalable system is 
also appropriate for the study of immu-
nomodulation in lymphoma and leuke-
mia cell lines.2 We were able to identify 
novel immunomodulatory agents and 
evaluate their effects across a panel 
of MM.1S, RPMI8226, KMS34 and 
Dox40 myeloma, as well as HT, Oci-Ly1 
and Farage lymphoma and KU812F 
leukemia cells. This broad approach 
allows for the understanding of the 
mechanisms shared by these tumor cell 
lines, each with its unique genetic back-
ground, oncogenic drivers and response 
to immunomodulation.
The role of the tumor microenviron-
ment in antitumor immunity is also well 
recognized,9,10 however, the ability to 
evaluate the interactions between tumor 
cells and their stroma at a preclinical level 
has been limited. Screening autologous 
stromal cells with immune effector cells, 
in the context of matched MHC antigens 
from cells isolated from the same patient, 
we observed that stromal cells inhibit 
antitumor immunity as provided by 
interleukin-2 (IL-2)-stimulated periph-
eral blood mononuclear cells (PBMCs).2 
Some drugs could counteract this effect, 
but not completely abrogate it. For 
example, stromal cells dramatically lim-
ited immune responses against MM.1S 
cells, yet lenalidomide or pomalidomide 
blocked such a stromal protection, indi-
cating part of the efficacy of clinically 
active therapies may result from the inhi-
bition of stromal mechanisms.
Arguably, the most important finding 
in our studies was that anticancer com-
pounds do not necessarily exert immuno-
stimulatory or immunosuppressive effects 
consistently across all tumor targets. We 
screened an 800 compound library and 
compared the consistency of immunomod-
ulatory effects against MM.1S myeloma 
vs. HT lymphoma cells. Only 2.1% of 
the library enhanced antitumor immunity 
the clinical success of immunomodulatory thalidomide derivatives has renewed the general interest in immunomodulatory 
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irrespective on whether they exert direct 
anticancer activity on not, will be facili-
tated by our methodology and other novel 
approaches. A comprehensive evaluation 
of these parameters is relevant not only 
for innate immune responses, but also 
for adaptive responses by T and dendritic 
cells. More broadly, immunologic thera-
pies enhancing graft-vs.-tumor (GVT) 
but not graft-vs.-host (GVH) mechanisms 
will be important to oncology patients eli-
gible to transplantation and will enable a 
more effective translation of preclinical 
discoveries to the bedside.
The development of first-in-class 
agents often requires a paradigm shift 
in thinking, along with enabling models 
and technologies. Historically, immune-
based models have relied on a single cell 
line, often being associated with difficul-
ties in the translation of in vitro results 
to patients. This translation might also 
have been complicated by the largely 
neglected role of the tumor microenviron-
ment and its influence on tumors targeted 
by immunomodulatory agents. The dis-
covery of first-in-class anticancer agents 
with immunomodulatory properties, 
against both MM.1S and HT cells, while 
7.5% had contrasting effects. This suggests 
that selection of the specific tumor model 
is a critical element for the development 
of immunomodulatory antitumor strate-
gies. Indeed, immunomodulatory drugs 
act not only on the host immune system 
but also on tumor and stromal cells, result-
ing in distinct outcomes depending on the 
precise interacting factors. The complexity 
of these interactions is daunting, but its 
understanding opens the door for the dis-
covery of agents that can modulate host-
tumor interactions at multiple levels.
Figure 1. Description of the compartment-specific bioluminescence (Cs-BLI) platform for antitumor immunity screening. Luciferase-positive tumor 
cells are mixed in culture with interleukin-2 (IL-2)-stimulated peripheral blood mononuclear cells (PBMCs). high-throughput screening for specific 
antitumor activity in the presence and absence of immune-effector cells is shown for ~100 small molecule inhibitors. Direct antitumor activity (black) 
of a given compound was compared with its modulation of antitumor effector activity (green). Direct activity is normalized to the untreated controls, 
whereas the effector cell-mediated activity is normalized to control conditions including the drug but not effector cells. effector cell-mediated data 
points (green) falling below the direct killing values (black) represent compounds that enhance antitumor immunity.1408  OncoImmunology  Volume 1 Issue 8
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